The purpose of this study was to investigate the clinical efficacy and safety of EGFR-TKI targeted drugs combined with HA-Gd2O3-NPs in non-small cell lung cancer (NSCLC). This evidence concerns the gene EGFR and non-small cell lung carcinoma.